Shopping Cart 0
Cart Subtotal
USD 0

Meda AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Meda AB (Meda), a subsidiary of Mylan NV is a specialty pharma company that develops, manufactures and markets prescription and non-prescription drugs. The company offers products in categories of respiratory, dermatology, pain and inflammation, Cx products, OTC products and others. Its respiratory products comprise Dymista, Aerospan, Epipen, Azelastine, Astepro, Novopulmon Novolizer, Formatris Novolizer and Pafinur, among others. The company offers stage clinical development, clinical trials and drug registration services. It operates in Armenia, Australia, Belgium, Brazil, China, Denmark, Egypt, Estonia, Finland, France, Germany, Hungary, Italy, Mexico, South Africa, the UAE, the UK and the US, among others. Meda is headquartered in Stockholm, Sweden.

Meda AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Meda AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meda AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Meda AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meda AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Meda AB, Medical Devices Deals, 2012 to YTD 2018 10

Meda AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Meda AB, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Rottapharm|Madaus Acquires Zyma Brands 12

Meda Acquires OTC Sleep Aid Product, MidNite 13

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 14

Private Equity 16

Riverside Acquires Euromed from Meda for USD86.7 Million 16

Partnerships 17

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 17

Equity Offering 18

Meda to Raise USD278.7 Million in Rights Offering 18

Rottapharm Withdraws IPO for USD614.7 Million 20

Debt Offering 21

Meda Prices Public Offering Of Notes Due 2018 For USD 92.4 Million 21

Meda Prices Public Offering Of Notes Due 2016 For USD 62 Million 22

Acquisition 23

Mylan Acquires Meda for USD9.42 Billion 23

Mylan Acquires Meda for USD9.9 Billion 25

Meda Acquires Rottapharm from Fidim for USD3 Billion 27

Fidim Acquires Rottapharm Biotech from Rottapharm 28

Meda Acquires ZpearPoint, Dental Products Provider 29

Meda Completes Acquisition Of Acton Pharma For Up To USD 200 Million 30

Meda AB-Key Competitors 32

Meda AB-Key Employees 33

Meda AB-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Meda AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Meda AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Meda AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Meda AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Meda AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meda AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Meda AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meda AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Meda AB, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Meda AB, Pharmaceuticals & Healthcare, Key Facts 2

Meda AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Meda AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Meda AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Meda AB, Deals By Therapy Area, 2012 to YTD 2018 8

Meda AB, Medical Devices Deals, 2012 to YTD 2018 10

Meda AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Rottapharm|Madaus Acquires Zyma Brands 12

Meda Acquires OTC Sleep Aid Product, MidNite 13

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 14

Riverside Acquires Euromed from Meda for USD86.7 Million 16

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 17

Meda to Raise USD278.7 Million in Rights Offering 18

Rottapharm Withdraws IPO for USD614.7 Million 20

Meda Prices Public Offering Of Notes Due 2018 For USD 92.4 Million 21

Meda Prices Public Offering Of Notes Due 2016 For USD 62 Million 22

Mylan Acquires Meda for USD9.42 Billion 23

Mylan Acquires Meda for USD9.9 Billion 25

Meda Acquires Rottapharm from Fidim for USD3 Billion 27

Fidim Acquires Rottapharm Biotech from Rottapharm 28

Meda Acquires ZpearPoint, Dental Products Provider 29

Meda Completes Acquisition Of Acton Pharma For Up To USD 200 Million 30

Meda AB, Key Competitors 32

Meda AB, Key Employees 33

Meda AB, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Meda AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.